Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half ...
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing small molecule therapeutics that address cancers and autoimmune diseases ...
Kronos Worldwide reports $18.1 million net income for Q1 2025, driven by increased sales and production volumes. Kronos Worldwide, Inc. announced a significant increase in its first-quarter 2025 net ...
LOS ANGELES, CA / ACCESS Newswire / January 20, 2026 / Kronos Advanced Technologies, Inc. ("Kronos" or the "Company") (OTC PINK:KNOS), a leader in innovative health and wellness technologies, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results